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Abstract: Propensity score analysis is a statistical approach to reduce bias often present in
non-randomized observational studies. In this paper we use this method to re-analyze data
from a study that assessed whether patients receiving HCV treatment from providers in
Project ECHO had different clinical outcomes than patients treated by specialists from an
academic medical center (UNM HCV clinic) but in which treatment assignment was not
randomized. We modeled the best estimated probability of treatment assignment, and then
assess differences overall SVR and SVR in patients with genotype 1 infection by treatment
arm using Stabilized Inverse Probability of Treatment Weights (SIPTW). Results show that
after adjustment for SIPTW, HCV treatment outcomes were signiﬁcantly better for the
ECHO patients compared to the UNM HCV clinic patients. Higher proportions of patients
treated by primary care providers achieved SVR and SVR with genotype 1 compared to
those treated at UNM HCV clinic with 15.1% and 16.3% absolute differences, respectively.
These results indicate that previously published results (showing no differences) were biased,
and resulted in an underestimation of the treatment effect of ECHO on HCV treatment.
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A prospective cohort study from 2004 through 2008, conducted by Arora et al,1 comparing HCV treatment outcomes in patients treated for hepatitis C virus (HCV) infection at
specialty clinics in an academic medical center (University of New Mexico (UNM)) and
patients treated by primary care providers in Project ECHO showed no differences in
sustained viral response (SVR) between the groups. A total of 57.5% (84 of 146) of
patients treated at UNM HCV clinic achieved SVR and 58.2% (152 of 261) patients
treated at ECHO sites achieved SVR. The difference in the proportion achieving SVR was
0.7 percentage points (95% conﬁdence interval (CI); −9.2 to 10.7; P=0.89). Among
patients with HCV genotype 1 infection, SVR was 45.8% (38 of 83 patients) at the
UNM HCV clinic and 49.7% (73 of 147 patients) at ECHO sites (P=0.57). The impact of
these results was signiﬁcant as they showed that complex interferon-based HCV treatment could be effectively delivered outside of specialty care using a telehealth knowledge
dissemination model. The ECHO (Extension for Community Healthcare Outcomes)
model, developed as a platform to deliver complex specialty medical care and improve
access of minorities and underserved populations to best practice care through an educational model of team-based interdisciplinary development - worked.1
This study’s limitations, however, were evident and discussed. As with many
observational studies of clinical care, this was not a randomized trial; in a randomized
149

submit your manuscript | www.dovepress.com

Hepatic Medicine: Evidence and Research 2019:11 149–152

DovePress

© 2019 Page et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

http://doi.org/10.2147/HMER.S212855

Dovepress

Page et al

trial patients and or providers would be randomly assigned
to treatment or control arms. With no control over treatment
assignment, treated – ECHO group, and non-treated- UNM
HCV clinic group, may have had large differences on their
observed covariates - imbalances, which could result in
biased estimates of the treatment effects. While the study
used a multivariable analysis approach to control for differences that were measured, such as race/ethnicity, age, and
other factors, this type of covariance analysis may still not
adequately eliminate bias. Thus, propensity score analysis
is a statistical approach to balancing covariates and reducing bias in analyses of non-randomized observational
studies.
We revisited the Project ECHO HCV study and utilized
the propensity score method to model the best estimated
probability of treatment assignment, and then assess differences in primary study outcomes including overall SVR
and SVR in patients with genotype 1 infection2 by treatment arm (ECHO vs. UNM HCV clinic).

Methods
We note that if the treatment effect were related to a
covariate, then an imbalance in the mean of this covariate
between the two arms of the study will tend to cause a
biased estimate of the treatment effect. Propensity score
analysis attempts to eliminate the bias in the covariate and
thereby give an unbiased estimate of the treatment effect.
Propensity scoring computes weights (to be used later in
weighted analyses) to modify the multivariate distribution
of covariates in the treatment and control arms in an
attempt to balance all covariates in mean simultaneously.
These weights are computed by considering treatment
versus control arms as a binary outcome and using logistic
regression to compute, as predicted values, the probabilities that the outcome = treatment arm given the covariate
values. With this conceptual/explanatory discussion given,
a technical description follows.
First, we conducted multiple logistic regression to build a
non-parsimonious model with the treatment versus control
arms as the outcome using all data on factors and covariates
that could potentially inﬂuence the treatment and possibly the
outcome3,4 as the independent variables. A total of 27 variables were included: age; sex; minority group (race/ethnicity);
marital status; employment status; housing status; HCV viral
load, body mass index (BMI); HCV genotype; creatinine,
hematocrit, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, total protein, albumin, white blood cell counts, platelet, absolute neutrophil
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counts; red-cell distribution width; mean corpuscular volume;
treatment completed status, treatment duration, follow up time
after treatment, and total follow up time. From this model, we
calculated the propensity score as the reciprocal of the probability of receiving the treatment that was actually received,
Inverse Probability of Treatment Weight (IPTW), and the
Stabilized Inverse Probability of Treatment Weight
(SIPTW).5 For our study we use SIPTW, which is an improvement over IPTW to reduce potential weights of subjects with
either low or high propensity scores.6 Parameter estimates for
this model were obtained by using the penalized likelihood to
avoid and minimize the chance of overﬁtting.7
The second step in the reanalysis was to apply the weights
to modeling the treatment outcomes (SVR and SVR in genotype 1 infection): adjusting by the SIPTWs to account for any
treatment selection bias. We use the area under the receiver
operating characteristic (ROC) curve to assess the discrimination power of the non-parsimonious model and HosmerLemeshow test to evaluate its calibration.8 To examine the
assumptions of common support and balance we explore both
the distribution of the propensity scores9,10 and SIPTWs for
the treatment (ECHO) and control (UNM HCV clinic)
respectively.

Results
The non-parsimonious model exhibited a high discrimination
power between the two treatment groups (ECHO vs. UNM
HCV clinic) with an area under the ROC curve of 0.880
(Figure 1). It also showed good calibration according to the
Hosmer-Lemeshow statistics (χ2 = 9.948, df = 8, P = 0.269).
The common support and balance assumptions were satisfactory for this problem. Speciﬁcally, the SIPTWs exhibited
similar distributions and the distributions of propensity
scores between the two treatments completely overlapped
between the two treatments with means close to one
(ECHO: M=1.0, SD=0.8; UNM HCV clinic: M=1.2,
SD=4.7), suggesting no misspeciﬁcation of the used model.11
Our results show that after adjustment for SIPTW,
HCV treatment outcomes were signiﬁcantly better for the
ECHO patients compared to the UNM HCV clinic patients
(Table 1). Higher proportions of patients treated by primary care providers achieved SVR and SVR with genotype 1 compared to those treated at UNM HCV clinic with
15.1% and 16.3% absolute differences, respectively.

Discussion
Our results indicate that by using propensity scoring with
measured covariates in this observational study, we reduced
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Figure 1 Left panel: ROC curve for classifying ECHO vs. UNM HCV clinic. Right panel: distribution of SIPTWs by treatment arm.

bias and achieved improved precision of the difference in
HCV treatment results for HCV infection in ECHO compared to UNM HCV clinic patients. And importantly, the
results show that patients treated by ECHO providers had
signiﬁcantly better outcomes than those treated by specialty
providers at the academic medical center. These results
indicate that previously published results (showing no differences) were biased, and resulted in an underestimation of
the treatment effect of ECHO on HCV treatment. Analyses
to further explore the sources of this bias showed three
factors that primarily contributed to the direction of the
adjusted ﬁndings: male sex, creatinine levels and white
blood cell count. For example, there were many more
males in ECHO (72%) than in UNM (45%) and males had
a somewhat lower SVR rate; this is a selection bias that
artiﬁcially caused ECHO to have a lower SVR rate than
would have been observed in a randomized clinical trial.
This analysis beneﬁtted from a large enough sample
size (406 patients: 261 were treated at ECHO sites and 146
were treated at UNM HCV clinic) to implement inverse
probability weighting. While there are several strategies
to building the multiple logistic regression models to

calculate the propensity scores, we used strategy which
utilizes a non-parsimonious model as recommended by
most authors.2,12–18 We had similar ﬁndings with better
outcomes in ECHO patients when we used a parsimonious
model using methods described by Shadish et al,14
wherein 19 covariates and factors were used instead of 27.
This previously published study is an important
example of how propensity scoring can (and should)
be used in statistical analysis in applied medicine,
where treatment assignment is not randomized. Further
these results conﬁrm previous ﬁndings showing that the
ECHO model is an effective way to deliver HCV treatment to in underserved communities. This research in
this study was conducted when interferon-based treatment was standard of care and treatment success rates
were much lower than with current direct-acting antiviral (DAA) treatments, which are effective in over 95%
of patients.19 As the ECHO model has now been
expanded into new clinical areas and populations
and with the new highly effective DAA treatment,
ongoing evidence will still be needed to measure effectiveness and impact. Using propensity scoring for

Table 1 HCV Treatment Outcomes By ECHO Vs. UNM HCV Clinic: Original Analyses Vs. Analyses Adjusted For SIPTW
Unadjusted (Previous Analysis)

Adjusted By SIPTW*

ECHO

ECHO

UNM HCV clinic

P-value

UNM HCV Clinic

p-Value

Proportion with SVR

58.2%

57.5%

0.890

58.1%

43.0%

0.003

Proportion of patients with HCV genotype 1 with SVR

49.7%

45.8%

0.572

48.2%

31.9%

0.008

Note: *Stabilized Inverse Probability of Treatment Weight.
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further observational analyses has important potential
provide unbiased and better estimates of these outcomes.
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